Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUN-0864 in Healthy Adults and Overweight/Obese Adults
NCT07905560Phase 1Not yet recruiting
- Sponsor
- Superluminal Medicines
- Start
- Nov 2026
- Primary completion
- Jan 2028
01
Overview
Phase 1, randomised, double-blind trial of SUN-0864 in obesity and Overweight (5 arms), sponsored by Superluminal Medicines. Primary endpoints: Treatment Emergent Treatment-Related Adverse Events, Maximum Observed Plasma Concentration and 5 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SUN-0864
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07905560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905560.